.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,759,029

« Back to Dashboard

Details for Patent: 6,759,029

Title: Delivery of rizatriptan and zolmitriptan through an inhalation route
Abstract:The present invention relates to the delivery of rizatriptan or zolmitriptan through an inhalation route. Specifically, it relates to aerosols containing rizatriptan or zolmitriptan that are used in inhalation therapy. In a composition aspect of the present invention, the aerosol comprises particles comprising at least 5 percent by weight of rizatriptan or zolmitriptan. In a method aspect of the present invention, either rizatriptan or zolmitriptan is delivered to a mammal through an inhalation route. The method comprises: a) heating a composition, wherein the composition comprises at least 5 percent by weight of rizatriptan or zolmitriptan, to form a vapor; and, b) allowing the vapor to cool, thereby forming a condensation aerosol comprising particles, which is inhaled by the mammal. In a kit aspect of the present invention, a kit for delivering rizatriptan or zolmitriptan through an inhalation route to a mammal is provided which comprises: a) a composition comprising at least 5 percent by weight of rizatriptan or zolmitriptan; and, b) a device that forms a rizatriptan or zolmitriptan containing aerosol from the composition, for inhalation by the mammal.
Inventor(s): Hale; Ron L. (Woodside, CA), Rabinowitz; Joshua D. (Mountain View, CA), Solas; Dennis W. (San Francisco, CA), Zaffaroni; Alejandro C. (Atherton, CA)
Assignee: Alexza Molecular Delivery Corporation (Palo Alto, CA)
Filing Date:May 22, 2002
Application Number:10/155,621
Claims:1. A composition for delivery of rizatriptan or zolmitriptan comprising a condensation aerosol a) formed by volatilizing rizatriptan or zolmitriptan under conditions effective to produce a heated vapor of the rizatriptan or zolmitriptan and condensing the heated vapor of the rizatriptan or zolmitriptan to form condensation aerosol particles, b) wherein said condensation aerosol particles are characterized by less than 5% rizatriptan or zolmitriptan degradation products, and c) wherein the aerosol MMAD is less than 3 microns.

2. The composition according to claim 1, wherein the mass of the condensation aerosol is at least 0.10 mg.

3. The composition according to claim 1, wherein the aerosol condensation particles are characterized by less than 2.5 percent by weight of rizatriptan or zolmitriptan degradation products.

4. The composition according to claim 1, wherein the condensation aerosol particles comprise at least 90 percent by weight of rizatriptan or zolmitriptan.

5. The composition according to claim 4, wherein the condensation aerosol has a mass median aerodynamic diameter less than 2 microns.

6. The composition according to claim 5, wherein the condensation aerosol particles comprise at least 97 percent by weight of rizatriptan or zolmitriptan.

7. A method of producing rizatriptan or zolmitriptan in an aerosol form comprising: a) volatilizing rizatriptan or zolmitriptan under conditions effective to produce a heated vapor of rizatriptan or zolmitriptan, and b) during said volatilizing, passing air through the heated vapor to produce aerosol particles of rizatriptan or zolmitriptan comprising less than 5% rizatriptan or zolmitriptan degradation products and an aerosol having an MMAD less than 3 .mu.m.

8. The method according to claim 7, wherein the aerosol particles are formed at a rate of greater than 0.5 mg/sec.

9. The method according to claim 7, wherein the mass of the aerosol is at least 0.10 mg.

10. The method according to claim 7, wherein said volatilizing includes heating a thin layer which includes the rizatriptan or zolmitriptan and which is on a solid support having the surface texture of a metal foil, to a temperature sufficient to volatilize the rizatriptan or zolmitriptan from the thin layer.

11. The method according to claim 7, wherein the particles comprise less than 2.5 percent by weight of rizatriptan or zolmitriptan degradation products.

12. The method according to claim 7, wherein the aerosol particles comprise at least 90 percent by weight of rizatriptan or zolmitriptan.

13. The method according to claim 12, wherein the aerosol has a mass median aerodynamic diameter less than 2 microns.

14. The method according to claim 13, wherein the aerosol particles comprise at least 97 percent by weight of rizatriptan or zolmitriptan.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc